UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14C INFORMATION

 

Information Statement Pursuant to Section 14 (c)

of the Securities Exchange Act of 1934

 

Check the appropriate box:

 

¨

Preliminary Information Statement

x

Definitive Information Statement

 

¨

Confidential, for Use of the Commission Only (as permitted by Rule 14c-5 (d)(2))

 

BLAKE INSOMNIA THERAPEUTICS, INC.

(Name of Registrant as Specified in Its Charter)

 

Payment of Filing Fee (Check the appropriate box):

 

x

No fee required.

 

¨

Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

 

1)

Title of each class of securities to which transaction applies:

 

2)

Aggregate number of securities to which transaction applies:

 

3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

4)

Proposed maximum aggregate value of transaction:

 

5)

Total fee paid:

 

¨

Fee paid previously with preliminary materials.

 

¨

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

 

1)

Amount Previously Paid:

 

2)

Form, Schedule or Registration Statement No:

 

3)

Filing Party:

 

4)

Date Filed:

 

 
 
 
 

BLAKE INSOMNIA THERAPEUTICS, INC .

244 5 TH AVENUE

SUITE A-154

N.Y, NEW YORK 10001

+1 (646) 453 4912

 

NOTICE OF ACTION BY

WRITTEN CONSENT OF MAJORITY STOCKHOLDERS

 

WE ARE NOT ASKING YOU FOR A PROXY

AND YOU ARE REQUESTED NOT TO SEND US A PROXY

 

THIS IS NOT A NOTICE OF A MEETING OF STOCKHOLDERS AND NO STOCKHOLDERS’

MEETING WILL BE HELD TO CONSIDER ANY MATTER DESCRIBED HEREIN.

 

To the Holders of Common Stock of Blake Insomnia Therapeutics, Inc.:

 

The accompanying Information Statement is being furnished to the holders of shares of the common stock of Blake Insomnia Therapeutics, Inc. (the "Company"), a Nevada corporation. The Board of Directors of the Company (the "Board") is not soliciting your proxy and you are requested not to send us a proxy. The purpose of this Information Statement is to notify you of actions already approved by written consent of the holder of a majority of the outstanding common stock (the “Majority Shareholder”) and the Board:

 

1.

To approve an amendment to the Articles of Incorporation of the Company to change the name of the Company to “BioHemp International, Inc.” (the “Name Change”).

 

The Name Change is hereinafter referred to as the “Current Action.”

 

The Current Action has been approved by the Board and the shareholders of action by written consent (the “Written Consent”) as of May 7th, 2019 (the “Record Date”), by the Majority Shareholder holding 99.94% of the voting rights of the outstanding shares of our common stock, par value $0.0001 per share (the “Common Stock”). In accordance with Rule 14c-2 promulgated under the Securities Exchange Act of 1934, as amended, the Current Action will become effective no sooner than twenty (20) days after we mail this notice and the accompanying Information Statement to our stockholders.

 

The written consent that we received constitutes the only stockholder approval required for the actions under Nevada law and, as a result, no further action by any other stockholder is required to approve the actions. We have not and will not be soliciting your approval of the Current Action.

 

This notice and the accompanying Information Statement are being mailed to our stockholders on or about June 12th, 2019.

 

This Information Statement is being provided to you pursuant to Rule 14c-2 under the Securities Exchange Act of 1934, as amended. It contains a description of the Current Action, as well as summary information regarding the transactions covered by the Information Statement. We encourage you to read the Information Statement thoroughly. You may also obtain information about us from publicly available documents filed with the Securities and Exchange Commission (the “SEC”). We may provide only one copy of the Information Statement to shareholders who share an address, unless we have received instructions otherwise. If you share an address, your household has received only one copy of this Information Statement and you wish to receive another copy, please contact our corporate secretary at the address or telephone number above. If you have received multiple copies and only wish to receive one copy of our SEC materials, you also may contact us at the address and phone number above.

 

By Order of the Board of Directors,

 

 

 

/s/ Daniel Blum

 

Daniel Blum

 

Sole Director

 

May 22nd, 2019

 

 

 
2
 
 

 

BLAKE INSOMNIA THERAPEUTICS, INC .

244 5 TH AVENUE

SUITE A-154

N.Y, NEW YORK 10001

+1 (646) 453 4912

 

INFORMATION STATEMENT

 

May 22nd , 2019

 

Action by Written Consent of Majority Shareholder

 

WE ARE NOT ASKING YOU FOR A

PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY

 

GENERAL INFORMATION

 

This Information Statement has been filed with the Securities and Exchange Commission and is being furnished, pursuant to Section 14C of the Exchange Act, to the shareholders (the “Shareholders”) of the Common Stock, of Blake Insomnia Therapeutics, Inc., a Nevada corporation (the “Company” or “Blake Insomnia”), to notify such Shareholders that on May 7th, 2019, the Board of Directors of the Company (the “Board”) and shareholder holding a majority of the voting rights of the outstanding shares of our common stock (the “Majority Shareholder”), par value $0.0001 per share (the “Common Stock”) approved and authorized the Company to file an amendment to the Articles of Incorporation of the Company to change the name of the Company to “BioHemp International, Inc.” (the “Name Change” or “Current Action”).

 

The Current Action was approved by Mr. Daniel Cattlin, the sole former member of our Board, and by FJ Investments International, Inc., which holds of approximately 99.94% of the outstanding voting capital stock of the Company. Following the filing of the preliminary information statement with the SEC, as discussed below, Daniel Blum was elected as a director of the Company and appointed as the sole officer of the Company, in connection with which, Mr. Cattlin resigned from the Board and from all positions with the Company.

 

“We,” “us,” “our,” the “Registrant” and the “Company” refers to Blake Insomnia Therapeutics, Inc., a Nevada corporation.

 

THE AMENDMENTS AND OTHER ACTIONS HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, NOR HAS THE SECURITIES AND EXCHANGE COMMISSION PASSED UPON THE FAIRNESS OR MERIT OF THE AMENDMENTS, OR THE OTHER ACTIONS NOR UPON THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED IN THIS INFORMATION STATEMENT ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

 

PLEASE NOTE THAT THIS IS NEITHER A REQUEST FOR YOUR VOTE NOR A PROXY STATEMENT, BUT RATHER AN INFORMATION STATEMENT DESIGNED TO INFORM YOU OF THE CHANGES THAT WILL OCCUR IF THE AMENDMENTS ARE COMPLETED AND TO PROVIDE YOU WITH INFORMATION ABOUT THE AMENDMENTS, THE OTHER ACTIONS AND THE BACKGROUND OF THESE TRANSACTIONS.

 

This Information Statement has been prepared by our management. The entire cost of furnishing this Information Statement will be borne by the Company. We will request brokerage houses, nominees, custodians, fiduciaries and other like parties to forward this Information Statement to the beneficial owners of our voting securities held of record by them and we will reimburse such persons for out-of-pocket expenses incurred in forwarding such material.

 

The Current Action will not become effective until at least 20 calendar days following the date of mailing of this Information Statement to our shareholders.

 

SUMMARY INFORMATION IN QUESTION AND ANSWER FORMAT

 

The following information in question and answer format summarizes many of the material terms of the Company’s proposed Current Action. For a complete description of the terms and conditions of the Current Action, you are advised to carefully read this entire Information Statement and the other documents referred to herein.

 

Why did I receive this Information Statement?

 

The Company’s transfer agent’s records show that you were a shareholder of the Company on the Record Date. As such, applicable laws require us to provide you information regarding the Actions even though your vote is neither required nor requested for the Actions to become effective.

 

 
3
 
 

 

Why am I not being asked to vote on the Current Action?

 

The holder of a majority of the issued and outstanding shares of Common Stock has already approved the Current Action pursuant to a written consent in lieu of a meeting. Such approval, together with the approval of the Company’s Board of Directors, is sufficient under Nevada law, and no further approval by our shareholders is required.

 

What Vote Is Required to Approve The Current Action?

 

Approval of the Current Action requires the affirmative vote of the holders of not less than a majority of the votes entitled to be cast by holders of record of the 25,032,517 issued and outstanding shares of common stock as of May 7th, 2019.

 

Who Voted in Favor of the Current Action?

 

The Shareholder owning an aggregate of 25,018,000 shares of our Common Stock, representing approximately 99.94% of the Common Stock. Such shareholder shall be referred to as the “Majority Shareholder.”

 

What Rights Do Shareholders Have to Dissent From the Current Action?

 

Company shareholders do not have dissenters’ rights or the right to seek the appraisal of their shares under Nevada law.

 

What do I need to do now?

 

Nothing. This information statement is purely for your information and does not require or request you to do anything.

 

FORWARD LOOKING STATEMENTS

 

This Information Statement contains or incorporates both historical and “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Words such as “anticipates,” “believes,” “expects,” “intends,” “future” and similar expressions identify forward-looking statements. Any such forward-looking statements in this report reflect our current views with respect to future events and financial performance and are subject to a variety of factors that could cause our actual results to differ materially from historical results or from anticipated results expressed or implied by such forward-looking statements. There may be events in the future that cannot be accurately predicted or over which the Company has no control. Shareholders should be aware that the occurrence of the events described in this Information Statement or in the documents incorporated herein by reference could have a material adverse effect on our business, operating results and financial condition or ability to consummate the transaction.

 

The forward-looking statements are not guarantees of future performance, events or circumstances, and actual results may differ materially from those contemplated by the forward-looking statements. Forward-looking statements herein or in documents incorporated herein by reference speak only as of the date of this Information Statement or the applicable document incorporated herein by reference (or such earlier date as may be specified therein), as applicable, are based on current assumptions and expectations or assumptions and expectations as of the date of the document incorporated herein by reference, and are subject to the factors above, among other things, and involve risks, events, circumstances, uncertainties and assumptions, many of which are beyond our ability to control or predict. You should not place undue reliance on these forward-looking statements. We do not intend to, and do not undertake an obligation to, update these forward-looking statements in the future to reflect future events or circumstances, except as required by applicable securities laws and regulations. The results presented for any period may not be reflective of results for any subsequent period.

 

You should carefully read and consider the cautionary statements contained or referred to in this section in connection with any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf, and all future written and oral forward-looking statements attributable to us or any other matters, are expressly qualified in their entirety by the foregoing cautionary statements.

 

ACTION TO BE TAKEN

 

This Information Statement contains a brief summary of the material aspects of the actions approved by the Board and the Majority Shareholder.

 

In accordance with Section 78.315 and 78.320 of the Nevada Revised Statutes, the following actions were taken based upon the recommendation and approval by the Company’s Board of Directors and the written consent of the Company’s shareholders.

 

 
4
 
 

 

AMENDMENT TO THE CERTIFICATE OF AMENDMENT OF THE ARTICLES OF INCORPORATION

 

On May 7th, 2019, our Board of Directors (the “Board”) adopted a resolution declaring it advisable to amend our Articles of Incorporation to effect the Current Action, wherein a prior name change, previously submitted to shareholders and approved was revoked. Our Board of Directors further directed that the new Certificate of Amendment of the Articles of Incorporation be submitted for consideration by our shareholders. By written consent, dated as of May 7th, 2019, the holders of a majority of the Company’s outstanding shares approved and adopted resolutions to amend the Company’s Articles of Incorporation to reflect the Current Action.

 

Reason for the Name Change

 

The Company’s Board has determined it to be in the best interests of the Company and its shareholders to change the Company’s business focus from within the medical sector. As disclosed in the Company’s public reports, the Company previously has been focusing on improving nighttime and daytime quality of life for people with insomnia. Due to the difficulties the Company has encountered with raising sufficient capital to implement the Company’s business strategy, the Board has considered various alternatives, and determined that it is in the best interests of the Company and its shareholders to transition to a new market and business focus.

 

The Company plans to focus on establishing a foothold on the fast-growing consumer hemp and cannabidiol (CBD) market. With the passage of the 2018 Farm Bill, which formally legalized hemp crop and its extracts, primarily CBD, the Board believes that the consumer market in the US is poised for exponential growth, with projections that the CBD market is expected to reach an estimated value of $22 billion by 2022.

 

The Company is looking to capitalize and leverage the public markets to acquire market share through consolidation and business acquisitions. The Company will seek to create a platform that will combine equity and capital to facilitate acquisitions of premium branded products.

 

The Board also believes that it is in the best interests of the Company to change the name of the Company to reflect the new business focus. The Company has begun the process of amending its articles of incorporation to change the name of the Company, which requires approval of the Board and the Shareholders. The Company will provide additional information about the name change, as well as the development of the new business strategies and their implementation, in the coming weeks.

 

Change in Management

 

On May 15, 2019, the Board voted to increase the size of the Board from one director to two directors, and to recommend that the shareholders of the Company elect Daniel Blum to serve as a member of the Board. Further, on May 15, 2019, the Majority Shareholder elected Daniel Blum to serve on the Board of the Company.

 

Additionally, on May 15, 2019, Mr. Cattlin, the Company’s President, Chief Executive Officer, Treasurer, and a member of the Board, submitted to the Company his resignation letter pursuant to which he resigned from his positions as President, Chief Executive Officer, Treasurer, and member of the Board. Mr. Cattlin’s resignation was not a result of any disagreements relating to the Company’s operations, policies or practices.

 

Also, on May 15, 2019, the Board accepted the resignation of Daniel Cattlin and appointed Daniel Blum to serve as the President, Chief Executive Officer, Secretary, and Treasurer of the Company.

 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

The following table sets forth information regarding the beneficial ownership of shares of our common stock as of the Record Date by:

 

 

●

Each of our directors;

 

 

 

●

Each of our named executive officers;

 

 

 

●

All of our directors and executive officers as a group; and

 

 

 

●

Each person known by us to beneficially own more than 5% of our outstanding common stock.

 

 
5
 
 

 

Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting and investment power with respect to the securities. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60 days of this Report are deemed outstanding. Such shares, however, are not deemed outstanding for purposes of computing the percentage ownership of any other person. To our knowledge, except as indicated in the footnotes to this table and subject to community property laws where applicable, the persons named in the table have sole voting and investment power with respect to all shares of our common stock shown opposite such person’s name. The percentage of beneficial ownership is based on 25,032,517 shares of our common stock outstanding as of May 7th, 2019.

 

Unless otherwise noted below, the address of the persons and entities listed in the table is c/o Blake Insomnia Therapeutics, Inc., 244 5th Avenue, Suite A-154, N.Y. New York 10001.

 

Name and Address of Beneficial Owner

 

Amount and

Nature of

Beneficial

Ownership

 

 

Percentage

of

Common Stock

Outstanding

 

 

 

 

 

 

 

 

FJ Investments International, Inc.

 

 

25,018,000

 

 

 

99.94 %

 

 

 

 

 

 

 

 

 

Daniel Blum, Director, President, CEO

 

 

0

 

 

 

0 %

 

 

 

 

 

 

 

 

 

Daniel Cattlin, Former Director, Former President and CEO

 

 

0

 

 

 

0 %

 

 

 

 

 

 

 

 

 

All Directors and Officers as a Group (1 person)

 

 

0

 

 

 

0 %

 

DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS

 

Regulations regarding the delivery of copies of proxy materials, information statements and annual reports to stockholders permit us, banks, brokerage firms and other nominees to send one annual report, proxy statement or information statement to multiple Shareholders who share the same address under certain circumstances, unless contrary instructions are received from Shareholders. This practice is known as “householding.” Shareholders who hold their shares through a bank, broker or other nominee may have consented to reducing the number of copies of materials delivered to their address. If, at any time, a Shareholder no longer wishes to participate in “householding” and would prefer to receive a single copy of annual reports, proxy statements, or information statements or to revoke a “householding” consent previously provided to a bank, broker or other nominee, the Shareholder must (1) notify its bank, broker or other nominee, as applicable, to revoke such consent or (2) direct its written or oral request to: Attn: Daniel Blum, Blake Insomnia Therapeutics, Inc., 244 5th Avenue Suite A-154, N.Y. New York 10001. Upon written or oral request, we will deliver promptly a separate copy of the annual report, proxy statement, or information statement, as applicable, to any Shareholder at a shared address to which a single copy of any of these documents was delivered.

 

Two or more Shareholders sharing an address can request delivery of a single copy of proxy statements, annual reports, or information statements, if they are receiving multiple copies by contacting the Company in the manner set forth above.

 

DISSENTER’S RIGHTS OF APPRAISAL

 

The Shareholders have no right under Nevada law, the Company’s and Restated Certificate of Incorporation consistent with above, or the Bylaws of the Company to dissent from any of the provisions adopted in the amendments.

 

 

6

 
 

 

ADDITIONAL INFORMATION

 

The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information including annual and quarterly reports on Form 10-K and 10-Q (the “1934 Act Filings”) with the Securities and Exchange Commission (the “Commission”). Reports and other information filed by the Company can be inspected and copied at the public reference facilities maintained at the Commission at Room 1024, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can be obtained upon written request addressed to the Commission, Public Reference Section, 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. The Commission maintains a web site on the Internet (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the Commission through the Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”).

 

 

 

By Order of the Board of Directors

 

 

 

 

Date: May 22nd, 2019

 

/s/ Daniel Blum

 

 

Daniel Blum

 

 
7